Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration

被引:27
作者
Malingré, MM
Schellens, JHM
van Tellingen, O
Rosing, H
Koopman, FJ
Duchin, K
Huinink, WWT
Swart, M
Beijnen, JH
机构
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands
[3] Univ Utrecht, Fac Pharm, Div Drug Toxicol, NL-3584 CA Utrecht, Netherlands
[4] Baker Norton Pharmaceut, Miami, FL 33137 USA
关键词
excretion; metabolism; oral administration; paclitaxel;
D O I
10.1097/00001813-200011000-00004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to compare the quantitative excretion of paclitaxel and metabolites after i.v. and oral drug administration. Four patients received 800 mg/m(2) paclitaxel orally 30 min after 15 mg/kg oral cyclosporin A, co-administered to enhance the uptake of paclitaxel. Three weeks later these and three other patients received 175 mg/m(2) paclitaxel by i.v. infusion. Blood samples, urine and feces were collected up to 48-96 h after administration, and analyzed for paclitaxel and metabolites. The area under the plasma concentration-time curve of paclitaxel after i.v, administration (175 mg/m(2)) was 16.2+/-1.7 muM . h and after oral administration (300 mg/m(2)) 3.8 +/- 1.5 muM . h. Following i.v. infusion of paclitaxel, total fecal excretion was 56+/-25%, with the metabolite 6 alpha -hydroxypaclitaxel being the main excretory product (37+/-18%). After oral administration of paclitaxel, total fecal excretion was 76+/-21%, Df which paclitaxel accounted for 61+/-14%. In conclusion, after i.v. administration of paclitaxel, excretion occurs mainly in the feces with the metabolites as the major excretory products, orally administered paclitaxel is also mainly excreted in feces but with the parent drug in highest amounts. We assume that this high amount of parent drug is due to incomplete absorption of orally administered paclitaxel from the gastrointestinal tract. [(C) 2000 Lippincott Williams & Wilkins.].
引用
收藏
页码:813 / 820
页数:8
相关论文
共 27 条
  • [1] RELATIVE PERFORMANCE OF SPECIFIC AND NONSPECIFIC FLUORESCENCE POLARIZATION IMMUNOASSAY FOR CYCLOSPORINE IN TRANSPLANT PATIENTS
    CHAN, GL
    WEINSTEIN, SS
    LEFOR, WW
    SPOTO, E
    KAHANA, L
    SHIRES, DL
    [J]. THERAPEUTIC DRUG MONITORING, 1992, 14 (01) : 42 - 47
  • [2] CRESTEIL T, 1994, CANCER RES, V54, P386
  • [3] GIBALDI M, 1992, PHARMACOKINETICS, P409
  • [4] HARRIS JW, 1994, CANCER RES, V54, P4026
  • [5] ISOLATION, STRUCTURAL DETERMINATION, AND BIOLOGICAL-ACTIVITY OF 6-ALPHA-HYDROXYTAXOL, THE PRINCIPAL HUMAN METABOLITE OF TAXOL
    HARRIS, JW
    KATKI, A
    ANDERSON, LW
    CHMURNY, GN
    PAUKSTELIS, JV
    COLLINS, JM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (05) : 706 - 709
  • [6] LIMITED SAMPLING STRATEGIES FOR INVESTIGATING PACLITAXEL PHARMACOKINETICS IN PATIENTS RECEIVING 175 MG/M(2) AS A 3-HOUR INFUSION
    HUIZING, MT
    VANWARMERDAM, LJC
    ROSING, H
    HUININK, WWTB
    STEWART, MB
    PINEDO, HM
    BEIJNEN, JH
    [J]. CLINICAL DRUG INVESTIGATION, 1995, 9 (06) : 344 - 353
  • [7] Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography
    Huizing, MT
    Sparreboom, A
    Rosing, H
    vanTellingen, O
    Pinedo, HM
    Beijnen, JH
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 674 (02): : 261 - 268
  • [8] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE QUANTITATIVE-DETERMINATION OF PACLITAXEL (TAXOL) IN HUMAN URINE
    HUIZING, MT
    ROSING, H
    KOOPMAN, F
    KEUNG, ACF
    PINEDO, HM
    BEIJNEN, JH
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 664 (02): : 373 - 382
  • [9] HUIZING MT, 1993, J CLIN ONCOL, V11, P2117
  • [10] Kumar G, 1995, CANCER CHEMOTH PHARM, V36, P129